Европейский союз - датский - EMA (European Medicines Agency)

eagle laboratories ltd.    - topotecan (as hydrochloride) - carcinoma; small cell lung carcinoma - antineoplastiske og immunomodulerende midler - topotecan monoterapi er indiceret til behandling af patienter med recidiveret småcellet lungekræft (sclc), for hvem genbehandling med førsteliniebehandling ikke anses for passende. topotecan i kombination med cisplatin er indiceret til patienter med carcinoma af livmoderhalsen tilbagevendende efter strålebehandling, og for patienter med stadium iv sygdom. patienter med tidligere udsættelse for cisplatin kræver en vedvarende behandling gratis interval til at retfærdiggøre, at behandling med kombination.

Европейский союз - датский - EMA (European Medicines Agency)

glaxo group ltd. - fondaparinuxnatrium - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - antitrombotiske midler - 5 mg / 0. 3 ml og 2. 5 mg / 0. 5 ml opløsning til injektion: forebyggelse af venøs tromboemboli (vte) hos patienter, som gennemgår større ortopædkirurgiske indgreb i underekstremiteterne, som hoftebrud, store knæoperationer eller hoftealloplastik. forebyggelse af venøs tromboemboli (vte) hos patienter, der gennemgår abdominal kirurgi, der vurderes at være i høj risiko for tromboemboliske komplikationer, såsom patienter, der gennemgår abdominal kræft kirurgi (se afsnit 5. forebyggelse af venøs tromboemboli (vte) i medicinske patienter, som vurderes at være i høj risiko for vte, og som er immobiliseret på grund af akut sygdom, såsom hjerte-insufficiens og/eller akut respiratorisk sygdomme, og/eller akut infektion eller inflammatorisk sygdom. , , 2. 5 mg / 0. 5 ml opløsning til injektion:, behandling af ustabil angina pectoris eller non-st-segment elevation myocardial infarction (ua/nstemi) i patienter, for hvem akut (< 120 min) invasive management (pci) er ikke indiceret (se afsnit 4. 4 og 5. behandling af st-segment elevation myocardial infarction (stemi) i patienter, der er lykkedes med trombolytika, eller som i første omgang er at modtage nogen anden form for terapi reperfusion. , , 5 mg/0. 4 ml, 7. 5 mg / 0. 6 ml og 10 mg / 0. 8 ml opløsning til injektion:, behandling af akut dyb venøs trombose (dvt) og behandling af akut lungeemboli (pe), undtagen i haemodynamically ustabile patienter eller patienter, der kræver thrombolysis eller pulmonal embolektomi.

Европейский союз - датский - EMA (European Medicines Agency)

nova laboratories ireland limited - hydroxycarbamid - anæmi, sickle cell - antineoplastiske midler - forebyggelse af vaso-okklusive komplikationer af seglcelleanæmi hos patienter over 2 år.

Европейский союз - датский - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft afvisning - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 15 mg

Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 20 mg

Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 25 mg

Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 30 mg

Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 35 mg

Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 40 mg